Compare QS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QS | ADPT |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 2020 | 2019 |
| Metric | QS | ADPT |
|---|---|---|
| Price | $5.44 | $24.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $9.38 | ★ $17.78 |
| AVG Volume (30 Days) | ★ 16.5M | 2.0M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.15 | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | $1,827.70 | $22.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $4.77 | $12.00 |
| 52 Week High | $19.07 | $26.87 |
| Indicator | QS | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 49.26 |
| Support Level | $4.77 | $23.92 |
| Resistance Level | $7.21 | $26.16 |
| Average True Range (ATR) | 0.26 | 1.07 |
| MACD | -0.02 | -0.25 |
| Stochastic Oscillator | 3.74 | 16.81 |
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional nodes. The company operates in one operating segment only.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.